The effect of oral micronized progesterone on first trimester screening test markers and neonatal outcome

Abstract

Objective: It was aimed to investigate whether or not nuchal translucency(NT) thickness, maternal serum free betahuman chorionic gonadotropin(β-hCG) and pregnancy-associated plasma protein-A(PAPP-A) levels may affected by the use of oral micronized progesterone(OMP) in first trimester pregnancies. Also we aimed to evaluate pregnancy outcome in pregnant women using OMP. Method: This study was performed retrospectively including 1192 pregnant women, between January 2015 and August 2017. Body mass index(BMI), maternal and gestational age, levels of maternal serum PAPP-A and free β-hCG, NT measurement and the crown-rump length(CRL), fetal sex, fetal birth weight, Apgar score 5thminute<7 and admission to neonatal intensive care unit(NICU) were evaluated. Results: Maternal characteristics, ultrasound and biochemical parameters, fetal characteristics and neonatal outcome were evaluated. There was no statistically significant difference for maternal age, BMI, gestational age, PAPP-A, β-hCG, CRL, NT thickness, fetal sex, fetal birth weight, Apgar score 5th minute <7 and the number of admission to NICU during the first 28 days.

Effect of Exogenous Progesterone on Fetal Nuchal Translucency: An Observational Study

“…Exogenous progesterone use has been found to increase the nuchal translucency of the fetus [11,12]. A few studies report the contrary [13][14][15]. Progesterone is being increasingly used in assisted reproductive technology (ART) cycles and threatened abortions.…”